Shih-chu
Senior Scientist
Pharmaceutical Sciences
Benitec Biopharma
Australia
Biography
Shih-Chu Kao is a Cellular and Molecular Biologist. She joined Benitec as a Senior Scientist in May 2014 and was one of the first two scientists who started the wet lab in Hayward, California. She is the lead scientist for Benitec’s Ocular Programs including Age-related Macular Degeneration. Shih-Chu acquired her first experience in developing ddRNAi-based therapy during her postdoc at Harvard Medical School studying Alzheimer’s disease. She was recruited to Tacere Therapeutics in 2008 and was one of the key scientists who developed TTO33X, series of compounds targeting Hepatitis C virus. During a brief break between Tacere and Benitec, Shih-Chu was the leader of the target validation group at Quanticel Pharmaceuticals, a small molecule drug company acquired by Celgene, developing epigenetic drugs targeting cancer stem cells.
Research Interest
Pharmaceutical Sciences
